Virtus Biotech ETF
11 hedge funds and large institutions have $1.94M invested in Virtus Biotech ETF in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
15% less funds holding
Funds holding: 13 → 11 (-2)
20.45% less ownership
Funds ownership: 33.36% → 12.91% (-20%)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
68% less capital invested
Capital invested by funds: $6.14M → $1.94M (-$4.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$107K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$33.9K |
| 3 |
LPL Financial
San Diego,
California
|
+$20.5K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$7.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.14M |
| 2 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$1.39M |
| 3 |
LCGC
Legacy Capital Group California
Los Gatos,
California
|
-$498K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$219K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$19.9K |
BBP Hedge Fund Activity: Q3 2023 in Review
11 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q3 2023, worth a combined $1.94M — down 68% from $6.14M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBP and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $107K. The largest seller was Morgan Stanley, cutting an estimated $2.14M.
- 11 institutional investors held Virtus Biotech ETF (BBP) as of Q3 2023, down from 13 in Q2 2023.
- Funds reported $1.94M of Virtus Biotech ETF stock for Q3 2023, down 68% quarter-over-quarter.
- 2 funds opened new Virtus Biotech ETF positions in Q3 2023 and 4 closed out, a net change of -2 holders.
- The largest Virtus Biotech ETF buyer in Q3 2023 was Susquehanna International Group, an estimated $107K added.
- The largest Virtus Biotech ETF seller in Q3 2023 was Morgan Stanley, an estimated $2.14M sold.
Based on aggregated 13F filings for Q3 2023.